Health collects data on the death of a woman in Marbella after being vaccinated

The Spanish Agency for Medicines and Health Products (AEMPS) is collecting data on the death of a 43-year-old teacher from Marbella, due to cerebral hemorrhage and who was vaccinated with AstraZeneca on March 3 to check if there was a relationship with the dose received , as sources from that agency have informed EFE.

The European Medicines Agency defends the AstraZeneca vaccine pending scientific evaluation on cases of thrombi

The European Medicines Agency defends the AstraZeneca vaccine pending scientific evaluation on cases of thrombi

Know more

This person has suffered an ischemic stroke with hemorrhagic transformation that has caused his death. Close sources have confirmed to the Malaga media that the woman, a teacher at a Marbella institute and without previous pathologies, received the first dose and went to the emergency room of a private hospital with symptoms that doctors attributed to side effects of the vaccine.

Days later, he returned to the health center, where he underwent several tests. In one of them a massive hemorrhage was detected in the brain. The woman was admitted over the weekend for a cerebral infarction and this Monday she underwent surgery without anything being able to do for her life. It is awaiting the autopsy to learn more details of what happened.

There are now three suspicions registered by the FEDRA of the Spanish Pharmacovigilance System, which is in charge of investigating the adverse effects of medications, of people vaccinated with the AstraZeneca antidote with cases of thrombosis. This is the only case in our country that has had a fatal outcome.

975,661 people have received the AstraZeneca vaccine in Spain. Three of them have presented thrombotic events in the 16 days after vaccination. However, the three cases have the particularity that thrombotic events have been associated with a decrease in the number of platelets in the blood. This fact may suggest an abnormal activation of the coagulation system that would be associated with this formation of clots in locations that are not the most common.

The Spanish Medicines Agency, together with the rest of the regulatory agencies and the European Medicines Agency, is gathering more information by carrying out an exhaustive investigation to find out if there is a relationship with the administration of the vaccine. The AEMPS will give a timely account of the result of this evaluation.

Spain has paralyzed Spain for 15 days vaccination with the Oxford / AstraZeneca serum while the European Medicines Agency (EMA) is carrying out a report on the cases of thrombi in people who had received this vaccine. About thirty episodes on more than five million people inoculated in the European Union, according to EMA data.

The Ministry of Health has taken this measure after Germany, France and Italy announced on Monday that they were temporarily suspending the use of the AstraZeneca product until the conclusions of the EMA are available. The alerts have been activated this weekend when several cases of rare cerebral thrombosis were detected in Europe, one of them in Spain. The Minister of Health, Carolina Darias, explained that after describing the episode in Spain, it was learned that there were some other cases in Norway and Germany. Darias has said that this type of thrombosis is different and rarer than those described last week and has been detected after the EMA and WHO explained last Friday that the AstraZeneca vaccine was still safe.


Source link